Watch for initiation of SCY-770 Phase 2 trial in Q4 2026 and any interim data in Q4 2027. Also monitor BARDA option exercises for SCY-247 funding. The cash runway into 2029 reduces near-term dilution risk.
Drugs in focus
SCYX drug pipeline →SCY-770
● Neutral Named in this press release- Impact
- Phase
- Phase 1 completed; Phase 2 ready
- Time to market
- Minimum 3-4 years, assuming positive Phase 2 data drives Phase 3 and potential accelerated approval via FDA-recognized surrogate endpoint (total kidney volume)
- Next catalyst
- None dated
What to watchWatch for the Phase 2 proof-of-concept study initiation in Q4 2026 (imminent) and, more importantly, the early efficacy readout on total kidney volume expected in the second half of 2027. SCY-770 must demonstrate a meaningful reduction in kidney growth versus placebo to justify the valuation implied by analyst targets (~$36 mean). Until then, the stock is driven by SCY-247 antifungal progress and the $214M BARDA contract, SCY-770 remains a high-risk/high-reward pipeline component.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $3.30entry
- T+1 · 11d ago +6.06%α +5.75% · $3.50
- T+5 · 5d ago +0.91%α −2.38% · $3.33
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Scynexis reported Q3 2026 net loss of $8.5M ($0.71 per share) vs consensus EPS of -$0.72, a slight beat. Revenue was $0 (no license revenue) vs consensus of $87K, a miss. The company highlighted a BARDA contract worth up to $214M for SCY-247 and a Phase 2 start for SCY-770 in ADPKD in Q4 2026. Cash of $63.2M is expected to fund operations into 2029.
Key Financial Metrics
Key Facts
- Net loss per share of $0.71 vs consensus of -$0.72 (beat by 1.4%)
- Revenue of $0 vs consensus of $87K (miss)
- BARDA contract up to $214M non-dilutive funding for SCY-247, $18.5M in initial base period
- Phase 1 of SCY-770 completed; Phase 2 in ADPKD expected to start Q4 2026
- Phase 1 of IV SCY-247 completed; Phase 2 planned for 2027
- Cash and investments $63.2M, expected to fund operations into 2029
- New CFO and SVP of R&D appointed
Financial Impact
Net loss of $8.5M, cash burn of ~$7.9M from Q2 2026; BARDA contract provides up to $214M non-dilutive funding if all options exercised
Risk Factors
- No revenue from license agreements; company is pre-revenue
- Phase 2 trial of SCY-770 may not meet endpoints
- BARDA may not exercise all options, limiting funding
- GSK relaunch of BREXAFEMME uncertain; milestone/royalty potential may not materialize
- Stock price volatility typical for clinical-stage biotech
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3396422 |
Track record
14 reports on SCYX
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +33.49% at T+20 after the May 11, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.91 Now $2.91 +0.00% settles Nov 24
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 Viewing Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $3.81 to $3.86 Now $2.91 −23.62% ▲ +1.31% +0.61% vs SPY
- Oct 6, 20265w ago Press Release Neutral 4/10 Entry $4.84 to $3.99 Now $2.91 −39.88% ▼ −17.56% −17.42% vs SPY
- Sep 28, 20267w ago Press Release Bullish 6/10 Entry $4.62 to $5.03 Now $2.91 −37.01% ▲ +8.87% +7.67% vs SPY
- Sep 22, 20267w ago 8-K Neutral 2/10 Entry $4.86 to $4.66 Now $2.91 −40.12% ▼ −4.12% −2.93% vs SPY
- Sep 10, 20269w ago 8-K Neutral 2/10 Entry $4.70 to $4.45 Now $2.91 −38.09% ▼ −5.32% −4.82% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $3.87 to $4.73 Now $2.91 −24.81% ▲ +22.22% +20.83% vs SPY
- May 22, 202625w ago 8-K Neutral 4/10 Entry $5.45 to $5.33 Now $2.91 −46.59% ▼ −2.17% −3.25% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers